{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:21:54Z","timestamp":1788909714525,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jneuroim.2019.577120","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:25:06Z","timestamp":1574681106000},"page":"577120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["MIF -173G\/C polymorphism is associated with NMO disease severity"],"prefix":"10.1016","volume":"339","author":[{"given":"Livnat","family":"Brill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Zveik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsan","family":"Haham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Benedek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2019.577120_bb0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1167\/iovs.11-8419","article-title":"Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice","volume":"53","author":"Adamus","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2015.10.007","article-title":"Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease","volume":"289","author":"Alexopoulos","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458517699791","article-title":"Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study","volume":"24","author":"Asgari","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WCO.0b013e3283533a3f","article-title":"Neuromyelitis optica: not a multiple sclerosis variant","volume":"25","author":"Barnett","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.gene.6363867","article-title":"A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis","volume":"3","author":"Baugh","year":"2002","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.201243162","article-title":"Partial MHC class II constructs inhibit MIF\/CD74 binding and downstream effects","volume":"43","author":"Benedek","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1712288114","article-title":"MIF and D-DT are potential disease severity modifiers in male MS subjects","volume":"114","author":"Benedek","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/365756a0","article-title":"MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia","volume":"365","author":"Bernhagen","year":"1993","journal-title":"Nature."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01878495","article-title":"The emerging role of MIF in septic shock and infection","volume":"8","author":"Bernhagen","year":"1994","journal-title":"Biotherapy."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0050","doi-asserted-by":"crossref","first-page":"14144","DOI":"10.1021\/bi00251a025","article-title":"Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF)","volume":"33","author":"Bernhagen","year":"1994","journal-title":"Biochemistry."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0055","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nm1567","article-title":"MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment","volume":"13","author":"Bernhagen","year":"2007","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jneuroim.2019.577120_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14728222.2019.1656718","article-title":"Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus","volume":"23","author":"Bilsborrow","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jneuroim.2019.577120_bb0065","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","article-title":"Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution","volume":"256","author":"Bizzoco","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2016.02.006","article-title":"Increased occurrence of anti-AQP4 seropositivity and unique HLA class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel","volume":"293","author":"Brill","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2019.577120_bb0075","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1007\/s10875-012-9781-1","article-title":"MIF alleles, and prospects for therapeutic intervention in autoimmunity","volume":"33","author":"Bucala","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.56.4.507","article-title":"MS and neuromyelitis optica in Martinique (French West Indies)","volume":"56","author":"Cabre","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/377068a0","article-title":"MIF as a glucocorticoid-induced modulator of cytokine production","volume":"377","author":"Calandra","year":"1995","journal-title":"Nature."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jneuroim.2018.04.006","article-title":"MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population","volume":"320","author":"Casta\u00f1eda-Moreno","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cyto.2015.11.021","article-title":"Association between high expression macrophage migration inhibitory factor (MIF) alleles and West Nile virus encephalitis","volume":"78","author":"Das","year":"2016","journal-title":"Cytokine."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0110","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0115","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1164\/rccm.200307-933OC","article-title":"Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and atopy","volume":"169","author":"Hizawa","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fgene.2018.00055","article-title":"Macrophage migration inhibitory factor \u2212173 G\/C polymorphism: a global meta-analysis across the disease Spectrum","volume":"9","author":"Illescas","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0125","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00415-013-6926-y","article-title":"The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom","volume":"260","author":"Jacob","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/jnnp-2014-308984","article-title":"Overlapping CNS inflammatory diseases: differentiating features of NMO and MS","volume":"86","author":"Jury\u0144czyk","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2019.577120_bb0140","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00415-012-6441-6","article-title":"Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study","volume":"259","author":"Ketelslegers","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0145","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74","volume":"197","author":"Leng","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0150","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0155","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.autrev.2006.02.008","article-title":"Neuromyelitis optica - Devic\u2019s syndrome, update","volume":"5","author":"Mandler","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ene.12714","article-title":"Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica","volume":"23","author":"Masuda","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0165","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.4049\/jimmunol.1303118","article-title":"HLA-DR\u03b11 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis","volume":"192","author":"Meza-Romero","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0170","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.0507189102","article-title":"Role for macrophage migration inhibitory factor in asthma","volume":"102","author":"Mizue","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0175","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/rheumatology\/41.5.558","article-title":"Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations","volume":"41","author":"Morand","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jneuroim.2019.577120_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","volume":"2012","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0185","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0195","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.4049\/jimmunol.175.9.5611","article-title":"Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis","volume":"175","author":"Powell","year":"2005","journal-title":"J. Immunol."},{"issue":"Suppl. 7","key":"10.1016\/j.jneuroim.2019.577120_bb0200","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1086\/432009","article-title":"Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases","volume":"41","author":"Renner","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0205","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1002\/art.30624","article-title":"Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus","volume":"63","author":"Sreih","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaut.2012.08.004","article-title":"A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance","volume":"40","author":"Vandenbark","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0220","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/art.22179","article-title":"Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma","volume":"54","author":"Wu","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2016.06.002","article-title":"The role of AQP4 in neuromyelitis optica: more answers, more questions","volume":"298","author":"Yang","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0230","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1172\/JCI81937","article-title":"Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus","volume":"126","author":"Yao","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2019.577120_bb0235","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1612717113","article-title":"MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis","volume":"113","author":"Yoo","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281930503X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281930503X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:35:13Z","timestamp":1759048513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557281930503X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":47,"alternative-id":["S016557281930503X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577120","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MIF -173G\/C polymorphism is associated with NMO disease severity","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577120"}}